Orbitrap Elite High-Resolution Mass Spectrometer for Proteomics and Metabolomics

描述(由申请人提供)：我们将使用LTQ-Orbitrap Elite(一种线性离子-陷阱-轨道-离子陷阱混合质谱仪)来支持一系列基础、转换和临床 德克萨斯大学安德森癌症中心(MDACC)的癌症研究项目以及德克萨斯医学中心(TMC)的合作研究。Orbitrap Elite的特点包括高质量分辨率(&gt；240,000)、大空间电荷容量、高质量精度(&lt；3ppm)、高达4000 m/z的质量/电荷范围以及大于103的动态范围。Orbitrap Elite的记录性能在三个关键领域超过了大多数替代仪器-分辨率、质量精度和扫描速度至少一个数量级。这些改进使Orbitrap成为蛋白质组和代谢组平台的最佳质谱仪，旨在识别和验证分子标记。它的高分辨率、精确的质量能力以前只能通过超导磁体系统实现。重要的是，这些能力在蛋白质复合体的分析、翻译后修饰、生物标记物发现(识别以前未识别的蛋白质和代谢物)以及早期验证研究方面做出了非凡的贡献。Orbitrap特别适用于使用稳定的同位素稀释质谱仪或蛋白质或代谢物的无标记定量的研究。我们预计，使用Orbitrap进行分子鉴定研究将立即改善人类癌症的诊断、治疗和预后，这与克莱伯格分子标记中心(蛋白质组学设施的所在地)改善癌症患者预后的目标一致。我们将使用拟议的Orbitrap Elite来支持至少7个NIH资助的R01、P01和孢子受赠者，并最终支持MDACC和TMC的许多其他NIH资助的项目。具体地说，我们计划将这种新的、改进的质谱仪应用于正在进行的乳腺癌、脑癌、卵巢癌和前列腺癌项目中蛋白质生物标记物的发现。通过识别和验证这些生物标记物并帮助识别新的药物靶标，该仪器将帮助我们通过改进癌症的诊断和治疗来改善公共健康。它将补充我们在克莱伯格分子标记中心以功能蛋白质组学为基础的个性化医疗计划，并最终改善每年在MDACC接受治疗的大量癌症患者的治疗，MDACC是美国最大和排名最高的癌症中心。

DESCRIPTION (provided by applicant): We will use the LTQ-Orbitrap Elite (a linear ion-trap-orbital ion-trap hybrid mass spectrometer) to support a range of basic, translational, and clinical cancer research projects at the University of Texas M. D. Anderson Cancer Center (MDACC) and in collaborative studies in the Texas Medical Center (TMC). The Orbitrap Elite features include high mass resolution (>240,000), large space charge capacity, high mass accuracy (<3 ppm), a mass/charge range of up to 4000 m/z, and dynamic range greater than 103. The documented performance of the Orbitrap Elite exceeds that of most alternative instruments in three critical areas by at least one order of magnitude-resolution, mass accuracy, and scan speed. Those improvements make the Orbitrap the optimal mass spectrometer for proteomic and metabolomic platforms aimed at identification and validation of molecular markers. Its high-resolution, accurate mass capabilities previously could only be achieved with superconducting magnet systems. Importantly, those capabilities have made extraordinary contributions to the analysis of protein complexes, post-translational modifications, and biomarker discovery (identification of previously unidentified proteins and metabolites) as well as early-stage validation studies. The Orbitrap is especially suitable for studies employing stable isotope-dilution mass spectrometry or label-free quantification of proteins or metabolites. We expect that using the Orbitrap for molecular identification studies will imminently improve the diagnosis, treatment, and prognosis of human cancers, in keeping with the goal of the Kleberg Center for Molecular Markers (where the Proteomics Facility is housed) to improve the outcomes of cancer patients. We will use the proposed Orbitrap Elite in support of at least 7 NIH-funded R01, P01, and SPORE grantees and eventually many other NIH-funded projects at MDACC as well as in the TMC. Specifically, we plan to apply this new, improved mass spectrometer to the discovery of protein biomarkers in ongoing projects in breast, brain, ovarian, and prostate cancers. By identifying and validating such biomarkers and helping to identify new drug targets, the instrument will help us improve public health through improvements in the diagnosis and treatment of cancer. It will complement our functional proteomics-based personalized medicine initiatives in the Kleberg Center for Molecular Markers and eventually improve treatment of the large number of cancer patients treated each year at MDACC, the largest and top ranked cancer center in the United States.